Pharmacological treatment of actinic keratosis

Ewa Zwierzyńska; Anna Zawistowska; Bogusława Pietrzak

doi:10.5114/dr.2016.61784

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2016
vol. 103

Send email

Copy url:

abstract:

Review paper

Pharmacological treatment of actinic keratosis

Ewa Zwierzyńska

,

Anna Zawistowska

,

Bogusława Pietrzak

Przegl Dermatol 2016, 103, 330–336

DOI: https://doi.org/10.5114/dr.2016.61784

Online publish date: 2016/09/01

View full text Get citation

PlumX metrics:

Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.

keywords:

Pharmacological treatment of actinic keratosis

Ewa Zwierzyńska , Anna Zawistowska , Bogusława Pietrzak

actinic keratosis, pharmacotherapy, clinical studies

Ewa Zwierzyńska

,

Anna Zawistowska

,

Bogusława Pietrzak